Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.16 +1.5%	$9.33	$3.26 ▼ $12.43	$1.82B	1.8	1.59 million shs	4.51 million shs
IMCR Immunocore	$32.02 +0.0%	$32.01	$23.15 ▼ $41.54	$1.61B	0.83	351,075 shs	223,455 shs
RAPP Rapport Therapeutics	$11.81 +0.7%	$10.92	$6.43 ▼ $29.74	$428.12M	N/A	165,154 shs	84,347 shs
SPRY ARS Pharmaceuticals	$18.08 +4.8%	$14.56	$7.89 ▼ $18.51	$1.70B	0.84	1.32 million shs	1.80 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.50%	+16.14%	+33.04%	+58.54%	+256.60%
IMCR Immunocore	+0.03%	+1.01%	-0.06%	+8.25%	-5.74%
RAPP Rapport Therapeutics	+0.68%	+7.07%	+17.63%	+17.51%	+1,180,999,900.00%
SPRY ARS Pharmaceuticals	+4.75%	+13.64%	+23.67%	+44.76%	+123.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8747 of 5 stars	1.4	1.0	4.2	3.1	2.5	0.6
IMCR Immunocore	2.3019 of 5 stars	4.3	0.0	0.0	2.2	2.5	0.0
RAPP Rapport Therapeutics	2.2328 of 5 stars	3.5	0.0	0.0	3.8	0.0	0.6
SPRY ARS Pharmaceuticals	3.2778 of 5 stars	3.6	2.0	0.0	2.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-13.06% Downside
IMCR Immunocore	2.55	Moderate Buy	$58.89	83.91% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	176.60% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	71.46% Upside

Current Analyst Ratings Breakdown

Latest RAPP, ADPT, IMCR, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/8/2025	IMCR Immunocore	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $86.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/14/2025	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$54.00 ➝ $50.00
4/10/2025	IMCR Immunocore	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$71.00 ➝ $71.00
4/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$28.00
4/8/2025	RAPP Rapport Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.32	N/A	N/A	$1.37 per share	8.88
IMCR Immunocore	$310.20M	5.18	N/A	N/A	$7.20 per share	4.45
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.35 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	19.92	$0.01 per share	2,038.19	$2.64 per share	6.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/6/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$3.45	N/A	N/A	N/A	N/A	-25.48%	-24.63%	8/14/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest RAPP, ADPT, IMCR, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
IMCR Immunocore	1.03	6.36	6.31
RAPP Rapport Therapeutics	N/A	31.01	31.01
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
IMCR Immunocore	84.50%
RAPP Rapport Therapeutics	N/A
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
IMCR Immunocore	10.40%
RAPP Rapport Therapeutics	N/A
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

RAPP, ADPT, IMCR, and SPRY Headlines

Recent News About These Companies

Leerink Partnrs Analysts Raise Earnings Estimates for SPRY

June 26 at 2:18 AM | americanbankingnews.com

Q2 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

June 25 at 6:12 AM | marketbeat.com

Harbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 25 at 5:27 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLC

June 25 at 5:02 AM | marketbeat.com

What is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?

June 25 at 2:54 AM | americanbankingnews.com

Brokers Offer Predictions for SPRY FY2029 Earnings

June 24 at 6:39 AM | marketbeat.com

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $240,000.00 in Stock

June 23, 2025 | americanbankingnews.com

Janney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 23, 2025 | marketbeat.com

Eric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

June 20, 2025 | marketbeat.com

249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource Council

June 20, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from Brokerages

June 19, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

June 15, 2025 | msn.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Estimates SPRY FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 6, 2025 | marketbeat.com

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 3, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's Why

May 31, 2025 | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025 | globenewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 Shares

May 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP, ADPT, IMCR, and SPRY Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.16 +0.18 (+1.50%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$12.30 +0.14 (+1.11%)

As of 08:00 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Immunocore NASDAQ:IMCR

$32.02 +0.01 (+0.03%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$32.06 +0.03 (+0.11%)

As of 06/26/2025 04:13 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Rapport Therapeutics NASDAQ:RAPP

$11.81 +0.08 (+0.68%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$11.84 +0.03 (+0.25%)

As of 06/26/2025 04:04 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

ARS Pharmaceuticals NASDAQ:SPRY

$18.08 +0.82 (+4.75%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.08 0.00 (-0.03%)

As of 08:00 AM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time